David Oliver, OD
Optometrist · Rock Hill, SCNPI 1679558399
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,199 of the $5,738 with a category attached, or 73.2%. 22 manufacturers reported payments, led by Coopervision Inc. at 24.8% of the total. Reporting peaked in 2019 at $2,063 and has fallen 69.9% since, to $620 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $51.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$526
- Tarsus Pharmaceuticals, Inc.$363
- Optos, Inc.$318
- Alcon$211
- plus $1K from 16 others
What the payments were for
- Consulting fees$2504%
- Travel & lodging$1,17620%
- Food & beverage$4,19973%
- Entertainment$1132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 18 | $1,425 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,413 |
| AbbVie(2 entities) | 15 | $526 |
| Tarsus Pharmaceuticals, Inc. | 10 | $363 |
| Optos, Inc. | 4 | $318 |
| Alcon | 7 | $211 |
| Aerie Pharmaceuticals, Inc. | 5 | $196 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $195 |
| Visionary Optics LLC | 1 | $148 |
| Oyster Point Pharma, Inc. | 6 | $143 |
| Sun Pharmaceutical Industries Inc. | 7 | $133 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Maculogix, Inc. | 1 | $109 |
| Bausch & Lomb Americas Inc. | 5 | $98 |
| Harrow Eye, LLC | 3 | $76 |
| Biotissue Holdings Inc. | 1 | $64 |
| Dompe US, Inc. | 2 | $43 |
| Shire North American Group Inc | 3 | $42 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Carl Zeiss Meditec USA, Inc. | 1 | $41 |
| Ivantis, Inc | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearScience Lipiflow System$1,176
- TearScience Lipiview System$1,176
- TearScience Lipiscan System$1,176
- MyDay Contact Lens$432
- PANORAMIC OPHTHALMOSCOPE$411
- Clariti Contact Lens$321
- Non-Product Brand Specific$250
- OCT OPHTHALMOSCOPE$206
- NFC-700$206
- VUITY$125
- Rhopressa$122
- Rocklatan$122
- LUMIGAN$113
- Hydrus Microstent$112
- AdaptDx$109
- MiSight Contact Lens$103
- P200DTx$102
- P200T$102
- P200TE$102
- P200TxE$102
How this compares
$5,738 in reported general payments places this provider in the 90th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 114 | $126,468 |
| XdemvyLotilaner | 27 | $47,547 |
| LumiganBimatoprost | 131 | $37,175 |
| Cyclosporine | 70 | $33,780 |
| Alphagan PBrimonidine Tartrate | 66 | $15,422 |
| TyrvayaVarenicline Tartrate | 15 | $12,704 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $8,592 |
| Brimonidine Tartrate | 69 | $6,977 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $6,178 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $5,907 |
| Travoprost | 38 | $4,110 |
| Brinzolamide | 14 | $3,043 |
| Latanoprost | 351 | $2,359 |
| Prednisolone Acetate | 53 | $1,434 |
| Dorzolamide Hcl | 43 | $803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $526 | $187,657351 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $363 | $47,54727 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $143 | $12,70415 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $196 | $6,17816 claims |
| AlconSimbrinza | $211 | $5,90726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Rock Hill
- Scott OliverRock Hill$16K
- Brandi M SalazarRock Hill$5K
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.